Koyfin Home > Directory > Health Care > Amicus Therapeutics > Capital Expenditures

Amicus Therapeutics Capital Expenditures Chart (FOLD)

Amicus Therapeutics annual/quarterly Capital Expenditures from 2006 to 2018.
  • Amicus Therapeutics Capital Expenditures for the quarter ending September 09, 2018 was $-3m a 58.07% decrease of -2m year over year
  • Amicus Therapeutics Capital Expenditures for the last 12 months ending September 09, 2018 was $-6m a 20.58% decrease of -1m year over year
  • Amicus Therapeutics Annual Capital Expenditures for 2017 was $-5m a -31.48% increase of 1m from 2016
  • Amicus Therapeutics Annual Capital Expenditures for 2016 was $-6m a 19.06% decrease of -1m from 2015
  • Amicus Therapeutics Annual Capital Expenditures for 2015 was $-5m a 95.06% decrease of -5m from 2014
Other Cash Flow Metrics:
  • Amicus Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-133m a 44.44% decrease of -59m year over year
  • Amicus Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $-78m a 35.32% decrease of -28m year over year
  • Amicus Therapeutics Total Revenue for the quarter ending September 09, 2018 was $21m a 28.49% increase of 6m year over year
View Chart On Koyfin

Quarterly FOLD Capital Expenditures Data

09/2018$-3m
06/2018$-1m
03/2018$-1m
12/2017$-1m
09/2017$-1m
06/2017$-2m
03/2017$-1m
12/2016$0m
09/2016$-1m
06/2016$-2m

Annual FOLD Capital Expenditures Data

2017$-5m
2016$-6m
2015$-5m
2014$0m
2013$-1m
2012$-4m
2011$-1m
2010$0m
2009$-2m
2008$-3m